RNA Analysis Market Research Report Information By Product & Service (Reagents/Consumables, Instrument, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Microarrays, Sequencing and RNA Interference), By Application (Drug Discovery, Clinical Diagnostics, Toxicogenomics and Comparative Transcriptomics), By End User (Pharmaceutical & Biotechnology Company, Hospitals & Diagnostic Centers, Academic & Research Institutes and CROs) And By Region (North America, Europe, Asia-Pacific and Rest Of The World) –Market Forecast Til

Global RNA Analysis Market Overview

The RNA Analysis Market was valued at USD 5.5 billion in 2022. The RNA Analysis market industry is projected to grow from USD 6.2 billion in 2023 to USD 18.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.20% during the forecast period (2024 - 2032).The increasing need for personalized medication, drug development and biopharmaceutical research are the primary market drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

RNA Analysis Market Trends

• Growing demand for reagents/consumables is driving the market growth.

The consumables and reagents are ready to use, making RNA analysis research and operations easier. The growing prevalence of infectious diseases and cancer is also expected to support the growth of reagents/consumables throughout the projection period, driving the market CAGR. Furthermore, the use of media and reagents in transcriptome studies is increasing, as is the need for high-quality reagents. The reagents/consumables category is growing due to the biotechnology industry's expanded R&D activities, government investment in life science research and the expanding field of integrated omics investigations. Human papillomavirus (HPV) and hepatitis are two viruses that can cause cancer; they represent over 30% of cancer cases in low- and lower-middle-income countries, according to the WHO's February 2022 update. Cancer is one of the leading causes of death globally. In medical specialties and diagnostic care facilities, there is a higher demand for diagnosis due to the increased prevalence of infectious diseases and cancer, which is anticipated to fuel segmental expansion over the study period. The market expansion has also been driven by the participants' launching of new products. In March 2021, for example, PCR Biosystems, a UK-based DNA and RNA analysis expert, introduced a line of Iso Fast BST Polymerase reagents for sensitive, fast and reliable RNA amplification. As a result of these product approvals, the market is expected to increase significantly over the analysis period.

A genetic disease that can be inherited or developed from certain environmental exposures, cancer is one of the most common genetic illnesses that are diagnosed. Prostate cancer led the list of cancer causes for men, while breast cancer led the list for women, according to the American Cancer Society's 2022 update. Also, according to the source above, the largest number of cancer cases, 1,117,640, were reported by individuals 65 years of age and older than by any other age group. RNA sequencing has been employed in numerous facets of cancer research and treatment, offering a useful method for identifying various cancer forms and other uncommon illnesses. Because of the rising prevalence of cancer and other disorders, there is a growing need for RNA analysis technologies, which is driving the market's expansion.

Furthermore, researchers may investigate complex tissues and varied cell populations with scRNA-Seq, uncovering unique cell types, subtypes and states that might be hidden in bulk RNA sequencing investigations. This richer awareness of cellular heterogeneity improves our comprehension of biological systems and disease pathogenesis. scRNA-Seq makes it possible to find and characterize rare cell populations important for development, disease progression and therapy response. Examples of these populations include immunological subsets, circulating tumor cells and stem cells. This has significant ramifications for targeted medicines, prognostics and diagnostics. Thus driving the RNA Analysis market revenue.

RNA Analysis Market Segment Insights

RNA Analysis Product & Service Insights

Based on Product & Service, the RNA Analysis market segmentation includes reagents/consumables, instruments, software and services. In 2023, the reagents/consumables segment dominated the market. Reagents and consumables are in high demand because of the increasing focus on RNA analysis in basic and translational research. RNA extraction kits, reverse transcription kits, PCR reagents and library preparation kits are only a few of the many reagents needed by academic institutions, research labs and biotechnology businesses to carry out RNA sequencing, qPCR, microarray analysis and other RNA analysis procedures.

The services category is anticipated to be the fastest growing. The need for RNA analysis services is predicted to rise in response to expanding government funding for life science research and pharmaceutical industry R&D activity. Numerous businesses actively provide RNA analysis services, such as transcriptome profiling, mRNA sequencing and end-to-end solutions like RNA sample preparation, library creation, sequencing and data analysis. These businesses include Eurofins Scientific, Genewiz and QIAGEN. The market is anticipated to grow in the upcoming years due to the availability of a wide range of services.

RNA Analysis Technology Insights

Based on Technology, the RNA Analysis market segmentation includes polymerase chain reaction (PCR), microarrays, sequencing and RNA interference. In 2023, the polymerase chain reaction (PCR) category generated the most income. Because of its great sensitivity and specificity, polymerase chain reaction (PCR) can accurately detect and quantify RNA targets, such as mRNA transcripts and non-coding RNAs, even at low expression levels. PCR allows for the rapid amplification of RNA targets in hours, facilitating rapid diagnostic and research turnaround times. By enabling real-time amplification kinetics monitoring, techniques like real-time quantitative PCR (qPCR) substantially improve efficiency.

The RNA analysis sequencing segment market is anticipated to grow fastest during the forecast period because of developments in SMRT and next-generation sequencing technologies. The industry is also being driven by the proliferation of businesses offering single-cell RNA sequencing services and the development of bioinformatics techniques. Furthermore, rising scientific awareness and reducing sequencing technology costs will drive the market throughout the estimated period.

Figure 1: RNA Analysis Market, by Technology, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

RNA Analysis Application Insights

Based on application, the RNA analysis market segmentation includes drug discovery, clinical diagnostics, toxicogenomics and comparative transcriptomics. The clinical diagnostics category leads the market. RNA analysis makes identifying cancer-specific gene signatures and molecular subtypes possible, especially when using methods like RNA sequencing and gene expression profiling. Accurate cancer diagnosis, subclassification and patient outcome prediction are made easier with this knowledge, which also influences therapy choices.

The RNA analysis market’s drug discovery segment is anticipated to grow fastest during the projection period. The identification and validation of biomarkers for prognosis, treatment response prediction and illness diagnosis are made possible by RNA analysis. Patient samples such as blood, tissue biopsies, or circulating tumor cells can be transcriptomic profiled to find RNA biomarkers linked to therapy resistance, disease progression and patient outcomes.

RNA Analysis End User Insights

Based on end user, the RNA Analysis market segmentation includes pharmaceutical & biotechnology company, hospitals & diagnostic centers, academic & research institutes and CROs. The hospitals & diagnostic centers category leads the market. RNA analysis is used by hospitals and diagnostic institutes to profile cancer tissues and categorize tumors according to molecular subtypes, patterns of gene expression and oncogenic pathways. In cancer practice, this genetic profiling helps with tumor categorization, patient stratification and targeted therapy selection.

The CROs segment of the RNA Analysis market is predicted to develop at the quickest rate over the projected period. The strategic activities of major market players aid the expansion of the segment. For example, in January 2022, 10x Genomics declared that three top CROs would be added to its 10x Certified Service Provider Network. The CROs and 10x Genomics will collaborate to assist top biopharmaceutical firms looking to leverage the single-cell and spatial technologies of 10x Genomics to speed up drug development and fuel innovative therapeutic discoveries. Azenta Life Sciences, Q2 Solutions and CellCarta are the three CROs selected for the 10x Genomics initiative.

RNA Analysis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American RNA Analysis market will dominate this market. Owing to the rapid advancement of structure-based medication designs, the growing focus on transcriptomics research and the significant investments made in biopharmaceutical research and development are all responsible for this supremacy. Furthermore, the notable increase in funding dedicated to pharmaceutical research and medication development is a major driver of revenue growth for businesses in this area. An increased market presence results from research and development endeavors coming together to create this dynamic landscape.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil.

Figure 2: RNA ANALYSIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's RNA Analysis market accounts for the second-largest market share because Europe has a thriving biotechnology and life sciences industry, with top universities, research centers and biotech firms actively engaged in the advancement of RNA analysis. This environment encourages creativity, teamwork and the commercialization of research results. Further, the German RNA Analysis market held the largest market share and the UK RNA Analysis market was the fastest-growing market in the European region.

The Asia-Pacific RNA Analysis Market is expected to grow at the fastest CAGR from 2024 to 2032. The rising levels of corporate and governmental funding promoting biotechnology research throughout the Asia-Pacific region serve as the foundation for this prediction. Particularly in the medical and life sciences fields, Japan has strong financing from both the public and private sectors to encourage the advancement of biotech research. This supportive atmosphere gives researchers the confidence to investigate the field of transcriptomics actively. Moreover, China’s RNA Analysis market held the largest market share and the Indian RNA Analysis market was the fastest-growing market in the Asia-Pacific region.

RNA Analysis Key Market Players & Competitive Insights

The RNA Analysis market will continue to grow due to major companies in the industry making significant R&D investments to extend their Product & Service ranges. Significant market developments include new Product & Service releases, contractual agreements, mergers and acquisitions, greater investments and cooperation with other organizations. Market participants also engage in various strategic actions to broaden their footprint. The RNA Analysis sector must provide affordable Products & Services to grow and thrive in a more cutthroat and dynamic market.

One of the main strategies manufacturers use in the worldwide RNA Analysis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the RNA Analysis sector. Major players in the RNA Analysis market, including Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN, Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Promega Corporation, GenXPro GmbH and others, are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc. (Thermo Fisher) supplies tools for medicine, analytical equipment, consumables and reagents, software and services for handling difficult analytical problems in clinical, research and diagnostic labs. It provides answers for synthetic biology, flow cytometry and cellular biology. Products from the company include technologies for molecular biology, genetic sequencing, electron microscopy, protein analysis and mass spectrometry. Serving the environmental, industrial quality and process control sectors, government organizations, academic and research institutions, pharmaceutical and biotech firms and clinical diagnostic labs. Thermo Fisher acquired Phitonex in January 2021 to expand its flow cytometry and imaging multiplexing capabilities for protein and cell analysis research needs. Phitonex expands the company's current portfolio of products for protein and cell analysis.

The life sciences business Eurofins Scientific SE (Eurofins) offers analytical testing services to customers in various industries. The company provides environmental testing, forensic services, geoscience services, food and feed testing, biopharma services, pharma discovery services, pharma early development, pharma central laboratory, biopharma product testing and product testing. Its analytical techniques support assessing biological products and chemicals' safety, identification, composition, origin, authenticity and purity. It uses its knowledge of information technology and logistics to provide various services. Eurofins purchased Beacon Discovery, a CRO focused on drug discovery, in March 2022. Beacon assisted with completely integrated drug discovery initiatives, ranging from pre-clinical candidates to target validation.

Key Companies in the RNA Analysis market include

• Thermo Fisher Scientific


• F. Hoffmann-La Roche Ltd


• Illumina, Inc


• QIAGEN


• Eurofins Scientific


• Merck KGaA


• Bio-Rad Laboratories, Inc.


• Agilent Technologies, Inc


• Promega Corporation


• GenXPro GmbH

October 2022:Agilent Technologies and CMP Scientific Corp. have partnered to offer an integrated capillary electrophoresis-mass spectrometry (CE-MS) solution to the pharmaceutical and life science sectors.

June 2022:Bio-Rad Laboratories, Inc. introduced the SEQuoia Express Stranded RNA Library Prep Kit. This kit facilitates RNA-sequencing procedures for Thorough Transcriptome Profiling and Researchers and biopharmaceutical scientists may easily build strong libraries with it.

RNA Analysis Market Segmentation

RNA Analysis Product & Service Outlook

• Reagents/Consumables


• Instrument


• Software


• Services

RNA Analysis Technology Outlook

• Polymerase Chain Reaction (PCR)


• Microarrays


• Sequencing


• RNA Interference

• Drug Discovery


• Clinical Diagnostics


• Toxicogenomics


• Comparative Transcriptomics

RNA Analysis End User Outlook

• Pharmaceutical & Biotechnology Company


• Hospitals & Diagnostic Centers


• Academic & Research Institutes


• CROs

RNA Analysis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America